Abstracts tagged "autoimmune diseases"

Abstract Number: 1644 • 2019 ACR/ARP Annual Meeting
Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial
Masataka Kuwana¹, Kristin Highland ², Martina Gahlemann ³, Christopher Denton ⁴, Aryeh Fischer ⁵, Maureen Mayes ⁶, Virginia Steen ⁷, Dinesh Khanna ⁸, Yannick Allanore ⁹, Mannaig Girard ¹⁰, Margarida Alves ¹¹, Susanne Stowasser ¹¹ and Oliver Distler ¹², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁵University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Georgetown University, Washington, D.C., USA, Georgetown, ⁸Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ¹⁰Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Patients with diffuse cutaneous systemic sclerosis (dcSSc) are at greater risk of developing interstitial lung disease (ILD) than patients with limited cutaneous systemic sclerosis…
Abstract Number: 104 • 2019 ACR/ARP Annual Meeting
Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders
Santosh Vishwakarma¹, Gurulingappa Hallur ¹, Himanshu Agrawal ¹, Sharad Singh ¹, Annasaheb Kalange ¹, Seema Chikkur Gangadhar ¹, Shuvranshu PraharaJ ¹, Nafees Ahmad Quresh ¹, Srikanth Kanagal Gopinath ¹, Krishnakumar V ¹, Sameer Mahmood ¹, Rudresh G ¹, Mohd Zainuddin ¹, Rajendra Kristam ¹, Ishtiyaque Ahmad ¹, Ramachandraiah Gosu ¹, Purra Buchi Reddy ¹, N V S K Rao ¹, Saloni Mehra ², Jeyaraj D A ¹, Takeshi Yura ¹, Saravanakumar dhakshinamoorthy ¹, Sriram Rajagopal ¹, Dhanalakshmi Sivanandhan ³ and Sridharan Rajagopal ³, ¹Jubilant Biosys, Bangalore, India, ²Jubilant Chemsys, Noida, India, ³Jubilant Therapeutics, Bangalore, India
Background/Purpose: Citrullination of proteins is catalyzed by a family of enzymes called the peptidylarginine deiminases (PADs). While the citrullinated proteins may have physiological roles in differentiation,…
Abstract Number: 1650 • 2019 ACR/ARP Annual Meeting
Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)
Joerg Henes¹, Maria Carolina Oliveira ², Myriam Labopin ³, Manuela Badoglio ⁴, Hans Ulrich Scherer ⁵, Nicoletta Del Papa ⁶, Thomas Daikeler ⁷, Marc Schmalzing ⁸, Roland Schroers ⁹, Thierry Martin ¹⁰, Grégory Pugnet ¹¹, Belinda Simoes ¹², David Michonneau ¹³, Erik Marijt ¹⁴, Bruno Lioure ¹⁵, Jacques Olivier Bay ¹⁶, John Snowden ¹⁷, Montserrat Rovira ¹⁸, Anne Huynh ¹⁹, Francesco Onida ²⁰, Lothar Kanz ¹, Zora Marjanovic ²¹ and Dominique Farge ²², ¹University Hospital Tuebingen, Department of Internal Medicine II (Oncology, Haematology, Immunology and Rheumatology), Tuebingen, Germany, ²Ribeirão Preto Medical School, University of São Paulo, Sao Paulo, Brazil, ³EBMT Paris Study Office, Saint Antoine Hospital, Université Pierre et Marie Curie, Paris, France, ⁴EBMT Paris Study Office, Hôpital St Antoine, Paris, France, ⁵Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁶Scleroderma Clinic, Osp. G. Pini, Department of Rheumatology, Milan, Italy, ⁷University and University Hospital of Basel, Department of Rheumatology, Basel, Switzerland, ⁸Universitätsklinikum Würzburg, Department of Rheumatology/ Clinical Immunology, Wuerzburg, Germany, ⁹University Hospital of Bochum, Med. Klinik, Bochum, Germany, ¹⁰Hôpitaux Universitaires de Strasbourg Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares Est-Sud-Ouest (RESO), Strasbourg, France, ¹¹CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹²Ribeirão Preto Medical School, University of São Paulo, Division of Hematology, Sao Paulo, Brazil, ¹³Hôpital Saint Louis & Université Paris 7, Denis Diderot, Department of Hematology, Paris, France, ¹⁴Leiden University Medical Center, Department of Hematology, Leiden, Netherlands, ¹⁵Strasbourg University Hospital, Department of Hematology, Strasbourg, France, ¹⁶CHU de Clermont Ferrand, Department of Hematology, Clermont Ferrand, France, ¹⁷Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, ¹⁸Hospital Clínic of Barcelona, Department of Haematology, Barcelona, Spain, ¹⁹UCT Oncopole, Department of Haematology, Toulouse, France, ²⁰Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, ²¹Saint Antoine Hospital, Department of Haematology, Paris, France, ²²Hôpital Saint-Louis, AP-HP Assistance Publique des Hôpitaux de Paris, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d’Ile-de-France, Filière ‘FAI2R’, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Université de Paris, EA 3518, Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada, Paris, France
Background/Purpose: TThree randomized controlled trials in systemic sclerosis (SSc) demonstrated that autologous hematopoietic stem cell transplantation (aHSCT) is superior to standard cyclophosphamide therapy. This EBMT…
Abstract Number: 120 • 2019 ACR/ARP Annual Meeting
Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease
Geoffrey Gillard¹, Jennifer Proctor ¹, Melissa Brooks ¹, Tahirih Lamothe ¹, Sharon Hyzy ¹, Sean McDonough ¹, Rahul Palchaudhuri ², Anjali Bhat ¹, Ganapathy Sarma ¹, Prashant Bhattarai ¹, Pranoti Sawant ¹, Brad Pearse ¹, Charlotte McDonagh ¹, Anthony Boitano ¹ and Michael Cooke ¹, ¹Magenta Therapeutics, Cambridge, MA, ²Magenta Therapeutics, Cambridge
Background/Purpose: Autologous hematopoietic stem cell transplant (autoHSCT) is a highly effective treatment in selected patients with autoimmune diseases. AutoHSCT can induce long-term remission (up to…
Abstract Number: 1807 • 2019 ACR/ARP Annual Meeting
Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease
George J. Kahaly ¹, Saba Sile ², Elizabeth H.Z. Thompson ², Thomas Vescio ³, Renee Perdok ³, Jeffrey W. Sherman³, Terry J. Smith ⁴ and Raymond S. Douglas ⁵, ¹Johannes Gutenberg University Medical Center, Mainz, Germany, ²Horizon Therapeutics plc, Brisbane, CA, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴University of Michigan Kellogg Eye Center, Ann Arbor, MI, ⁵Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Thyroid eye disease (TED) is a debilitating autoimmune disorder characterized by inflammation and exophthalmia along with significantly altered appearance and vision changes. TED is…
Abstract Number: 253 • 2019 ACR/ARP Annual Meeting
A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease
Maria Lopez-Olivo¹, Noha Abdel-Wahab ¹ and Maria E. Suárez-Almazor ², ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are increasingly used in the treatment of cancer. To date, no clinical trials exist evaluating the use of ICI in…
Abstract Number: 1833 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial
Kristin Highland¹, Oliver Distler ², Masataka Kuwana ³, Yannick Allanore ⁴, Shervin Assassi ⁵, Arata Azuma ⁶, Arnaud Bourdin ⁷, Christopher Denton ⁸, Jörg Distler ⁹, Anna Maria Hoffmann-Vold ¹⁰, Dinesh Khanna ¹¹, Maureen Mayes ⁵, Ganesh Raghu ¹², Madelon Vonk ¹³, Martina Gahlemann ¹⁴, Mannaig Girard ¹⁵, Susanne Stowasser ¹⁶, Donald Zoz ¹⁷, Aryeh Fischer ¹⁸ and Toby Maher ¹⁹, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁶Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ⁷PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214 and Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, Montpellier, France, Montpellier, ⁸University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ¹⁰Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²University of Washington, Seattle, USA, Seattle, ¹³Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ¹⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹⁵Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ¹⁸University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ¹⁹National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the annual rate of decline in forced vital capacity…
Abstract Number: 374 • 2019 ACR/ARP Annual Meeting
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Eric Matteson¹, Clive Kelly ², Jörg Distler ³, Anna Maria Hoffmann-Vold ⁴, James Seibold ⁵, Shikha Mittoo ⁶, Oliver Distler ⁷, Rainer-Georg Goeldner ⁸, Rozsa Schlenker-Herceg ⁹, Susanne Stowasser ¹⁰, Manuel Quaresma ¹⁰ and Kevin Flaherty ¹¹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ⁶University Health Network, Toronto, Ontario, Canada, Toronto, Canada, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
Abstract Number: 2033 • 2019 ACR/ARP Annual Meeting
IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells
Angie Hammond¹, Sean Parghi ¹, Nathan Wright ¹, Ethan Grant ¹, James Taylor ¹ and Matthew Warr ¹, ¹Gilead Sciences, Inc., Foster City, CA
Background/Purpose: A hallmark of lupus is the presence of antinuclear autoantibodies, including those against RNA-protein complexes and double-stranded DNA (dsDNA).1,2 FcγR-mediated internalization of these nucleic…
Abstract Number: 712 • 2019 ACR/ARP Annual Meeting
Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics
Oliver Distler¹, Kristin Highland ², Maureen Mayes ³, Masataka Kuwana ⁴, Lesley Saketkoo ⁵, Madelon Vonk ⁶, Michael Kreuter ⁷, Laura Hummers ⁸, Ute von Wangenheim ⁹, Martina Gahlemann ¹⁰, Veronika Kohlbrenner ¹¹, Margarida Alves ¹², Emmanuelle Clerisme-Beaty ¹² and Arata Azuma ¹³, ¹Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁶Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ⁷Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ⁹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, ¹⁰Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹³Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), the adverse events associated with nintedanib were manageable for most patients…
Abstract Number: 2075 • 2019 ACR/ARP Annual Meeting
Cross-sectional Study and Mendelian Randomization Analysis of Diet in Six Prevalent Autoimmune Diseases
Antonio Julià¹, Sergio H Martinez ², Jesús Tornero ³, Juan Cañete ⁴, Antonio Fernández-Nebro ⁵, Francisco J. Blanco ⁶, Jesús Rodríguez ⁷, Francisco Javier Lopez-Longo ⁸, Benjamín Fernandez-Gutierrez ⁹, Jordi Gratacós ¹⁰, Jose J Pérez Venegas ¹¹, Carolina Pérez ¹², Ruben Queiró ¹³, Alejandro Olivé-Marqués ¹⁴, Mercedes Alperi-López ¹⁵, Carlos Montilla ¹⁶, José Luís Andreu ¹⁷, Juan Carlos Torre-Alonso ¹⁸, Mª Ángeles Aguirre-Zamorano ¹⁹, Hèctor Corominas ²⁰, Paloma Vela ²¹, Víctor Martínez-Taboada ²², Sara Marique ²³, Joan M Nolla ²⁴, Isidoro Gonzalez ²⁵, Santiago Muñoz-Fernandez ²⁶, José Luís Marenco de la Fuente ²⁷, Carlos González ²⁸, Antonio Zea ²⁹, Maria Lopez Lasanta ³⁰, Daniel Roig ³¹, Jose Maria Pego-Reigosa ³², Mireia Lopez Corbeto ³³, Pedro Zarco ³⁴, Mercedes Freire González ³⁵, Alba Erra ³⁶, Elvira Díez ³⁷, Santos Castañeda ³⁸, Esther Rodriguez ³⁹, Alicia García ⁴⁰, Patricia Carreira ³⁹, Georgina Salvador ⁴¹, Ricardo Blanco ⁴², Cesar Diaz-Torne ⁴³, Alfredo Willisch Domínguez ⁴⁴, Joan Antonio Mosquera ⁴⁵, Simón Sánchez-Fernández ⁴⁶, Júlio Ramírez ⁴⁷ and Sara Marsal ⁴⁸, ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ³Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Castilla-La Mancha, Spain, ⁴Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ⁵Hospital Carlos Haya, Malaga, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ⁷Hospital Universitario de Bellvitge, Hospitalet, Spain, ⁸Hospital Universitario Gregorio Marañón, Madrid, Madrid, Spain, ⁹Hospital Clínico San Carlos, Madrid, Madrid, Spain, ¹⁰Hospital Parc Taulí, Sabadell, Catalonia, Spain, ¹¹Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ¹²Parc de Salut Mar, Barcelona, Barcelona, Spain, ¹³Hospital Universitario Central de Asturias, Oviedo, Oviedo, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ¹⁵Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁷Hospital Puerta de Hierro, Madrid, Madrid, Spain, ¹⁸Hospital Monte Naranco, Oviedo, Spain, ¹⁹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain, ²¹Hospital General Universitario de Alicante, Alicante, Spain, ²²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²³Hospital Regional Univeristario de Málaga, Málaga, Spain, ²⁴Hospital Universitari de Bellvitge, Hospitalet, Spain, ²⁵Hospital Universitario La Princesa, Madrid, Spain, ²⁶Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ²⁷Hospital Valme, Sevilla, Sevilla, Spain, ²⁸Hospital Universitario Gregorio Marañón, Madrid, Spain, ²⁹Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³⁰Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³¹Hospital Moisès Broggi, Barcelona, Sant Joan Despí, Barcelona, Singapore, ³²Complexo Hospitalario Universitario, Vigo, Spain, ³³Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, ³⁴Hospital Universitario Fundación Alcorcón, Madrid, Madrid, Spain, ³⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ³⁶H Sant Rafael, Barcelona, Barcelona, Spain, ³⁷Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ³⁸Rheumatology, Hospital Universitario La Princesa, Madrid, Madrid, Spain, ³⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴⁰Centro de Salud Virgen de los Reyes, Sevilla, Sevilla, Spain, ⁴¹Hospital Mútua Terrassa, Terrassa, Spain, ⁴²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴³Hospital de la Santa Creu i Sant Pau, barcelona, Catalonia, Spain, ⁴⁴Complexo Hospitalario de Ourense, Ourense, Spain, ⁴⁵Complejo Hospitalario Hospital Provincial de Pontevedra, Pontevedra, Spain, ⁴⁶Hospital La Mancha Centro, Alcázar de San Juan, Alcázar de San Juan, Spain, ⁴⁷Hospital Clínic de Barcelona, Barcelona, Spain, ⁴⁸Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Autoimmune diseases (AD) are complex diseases associated with both genetic and environmental risk factors. In the last 10 years major advances have been made…
Abstract Number: 826 • 2019 ACR/ARP Annual Meeting
Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death
Meifang Wu¹, Eric Yen ² and Ram Raj Singh ², ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²UCLA, Los Angeles
Background/Purpose: Almost every organ system can be affected by primary immune-mediated diseases characterized by inflammation and therapeutic response to immune-suppressive or anti-inflammatory drugs. These diseases…
Abstract Number: 2114 • 2019 ACR/ARP Annual Meeting
Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Daisuke Kobayashi¹, Sayuri Takamura ², Yoko Wada ³, Takeshi Kuroda ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, ³Niigata Rinko Hospital, Niigata, Niigata, Japan, ⁴Health administration office, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections.…
Abstract Number: 880 • 2019 ACR/ARP Annual Meeting
Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development
Matthew Woodruff¹, Christopher Tipton ¹, Jennifer Hom ¹ and Iñaki Sanz ¹, ¹Emory University, Atlanta, GA
Background/Purpose: Lupus nephritis (LN) is an autoimmune destruction of the kidney glomeruli and loss of kidney function affecting almost half of lupus patients. Although the…
Abstract Number: 2150 • 2019 ACR/ARP Annual Meeting
Frequency of Polyautoimmunity in a Tertiary Hospital
Elena Grau García¹, José Ivorra Cortés ¹, Jorge Juan Fragio Gil ¹, Roxana Gonzalez Mazarío ¹, Marta de la Rubia Navarro ¹, Cristóbal Pavez Perales ¹, Cristina Alcañiz Escandell ¹, Inmaculada Chalmeta Verdejo ¹, Luis González Puig ¹, Isabel Martínez Cordellat ¹, Rosa Negueroles Albuixech ¹, José Eloy Oller Rodríguez ², Francisco Miguel Ortiz-Sanjuán ¹, Elvira Vicens Bernabeu ¹, Carmen Nájera Herranz ¹, Inés Cánovas Olmos ¹, Samuel Leal Rodriguez ¹ and José Andrés Román Ivorra ¹, ¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Rheumatology Department. HUP La Fe, v, Comunidad Valenciana, Spain
Background/Purpose: Polyautoimmunity (PAI) is the presence of more than one Autoimmune Disease (AID) in one patient. PAI have been reported in different AIDs as systemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].